Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ieper – page 8

1 838 clinical trials in Ieper, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ieper at a glance
1 838
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 838 trials in Ieper

Open in trial search

Efficacy and Safety of BI 1015550 in Adults with Fibrosing Interstitial Lung Disease at Risk of Disease Progression: A Randomized, Placebo‑Controlled Trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:PIPE-791
  • Sponsor:Contineum Therapeutics Inc.

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Astellas Pharma Global Development Inc.

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Ifinatamab deruxtecan in Patients With Advanced Esophageal Squamous Cell Carcinoma

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Merck Sharp & Dohme LLC

Short-course (7‑day) versus standard 14‑day ciprofloxacin treatment for men with serious urinary tract infection

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:UZ Brussel

Anaemia+1

Recruiting

A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Gastric cancer+2

Recruiting

A study of pumitamig and a drug combination versus nivolumab and a drug combination for patients with untreated advanced or metastatic stomach or esophageal cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ieper

What the registry says about research in the country

01 Infectious Disease Prevention

Research focusing on developing and evaluating vaccines against influenza and respiratory syncytial virus in various age groups. Multiple trials are investigating immune responses and safety profiles in both younger and older adults.

  • Influenza vaccine studies in adults 60+ years
  • RSV vaccine trials for elderly population
  • UTI vaccine development

Advanced clinical research aims to enhance protection against common respiratory infections and urinary tract pathogens.

02 Kidney Disease Management

Comprehensive studies evaluating innovative treatments for chronic kidney disease (CKD), particularly in patients with concurrent conditions like hypertension and diabetes.

  • Combined therapy approaches
  • Novel drug evaluations
  • Albumin reduction strategies

Multiple trials are exploring combination therapies and new compounds to improve outcomes in CKD patients.

03 Cardiovascular and Metabolic Disorders

Innovative research addressing cardiovascular conditions and metabolic disorders, including studies on atrial fibrillation and diabetes prevention.

  • Post-gestational diabetes interventions
  • Atherosclerotic disease in ESKD
  • Antiplatelet therapy optimization

Trials focus on both preventive measures and treatment strategies for complex cardiovascular conditions.

04 Oncology Research

Advanced studies in cancer treatment, particularly focusing on mantle cell lymphoma and endometrial cancer therapies.

  • Lymphoma combination treatments
  • Endometrial cancer maintenance therapy
  • Novel therapeutic approaches

Research aims to improve treatment outcomes through innovative drug combinations and maintenance strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.